The Predictive Value of Periostin to Diagnose Crohn’s Disease
Main Article Content
Abstract
Background: There is still no sensitive and specific biomarker that can be used in the diagnosis and follow-up of Crohn’s disease, so we
aimed to assess the diagnostic accuracy of serum periostin levels in Crohn’s disease.
Methods: The study included 40 Crohn’s disease patients aged 18-70 years and considered in remission (Crohn’s Disease Activity Index
< 150) at admission. Forty healthy volunteers were included in the study as the control group. Crohn’s patients were divided into 3 main
groups as <4 years, 4-8 years, and >8 years according to the follow-up period (in the group <4 years, it was subdivided into <2 and
2-4 years). Serum periostin levels were studied by enzyme-linked immunosorbent assay.
Results: Forty Crohn’s disease patients and 40 control participants were included in the study. In the Crohn’s disease group, serum
periostin level was 36.55 ng/mL, while it was 21 ng/mL in the control group, P < .001. Periostin levels in the Crohn’s disease group were
higher in the groups with disease duration <4 years, 4-8 years, and >8 years compared to the control group (P < .001, P < .001, P =
.038, respectively). For the diagnosis of Crohn’s disease independent of disease duration, the cut-off periostin level was determined as
27.8 ng/mL, while the sensitivity and specificity for this value were 72.5% and 77.5%, respectively.
Conclusion: Serum periostin levels of the patients followed up with the diagnosis of Crohn’s disease in remission were found to be significantly higher than the healthy individuals, and cut-off values of serum periostin were obtained to both diagnose Crohn’s disease and
predict the course of the disease.
aimed to assess the diagnostic accuracy of serum periostin levels in Crohn’s disease.
Methods: The study included 40 Crohn’s disease patients aged 18-70 years and considered in remission (Crohn’s Disease Activity Index
< 150) at admission. Forty healthy volunteers were included in the study as the control group. Crohn’s patients were divided into 3 main
groups as <4 years, 4-8 years, and >8 years according to the follow-up period (in the group <4 years, it was subdivided into <2 and
2-4 years). Serum periostin levels were studied by enzyme-linked immunosorbent assay.
Results: Forty Crohn’s disease patients and 40 control participants were included in the study. In the Crohn’s disease group, serum
periostin level was 36.55 ng/mL, while it was 21 ng/mL in the control group, P < .001. Periostin levels in the Crohn’s disease group were
higher in the groups with disease duration <4 years, 4-8 years, and >8 years compared to the control group (P < .001, P < .001, P =
.038, respectively). For the diagnosis of Crohn’s disease independent of disease duration, the cut-off periostin level was determined as
27.8 ng/mL, while the sensitivity and specificity for this value were 72.5% and 77.5%, respectively.
Conclusion: Serum periostin levels of the patients followed up with the diagnosis of Crohn’s disease in remission were found to be significantly higher than the healthy individuals, and cut-off values of serum periostin were obtained to both diagnose Crohn’s disease and
predict the course of the disease.